ClariVest Asset Management LLC Has $70.51 Million Holdings in Amgen, Inc. (AMGN)

ClariVest Asset Management LLC reduced its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 6.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 340,163 shares of the medical research company’s stock after selling 24,305 shares during the quarter. Amgen accounts for approximately 1.2% of ClariVest Asset Management LLC’s investment portfolio, making the stock its 14th biggest holding. ClariVest Asset Management LLC’s holdings in Amgen were worth $70,512,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Cornerstone Wealth Management LLC boosted its holdings in Amgen by 20,035.7% in the 2nd quarter. Cornerstone Wealth Management LLC now owns 287,337 shares of the medical research company’s stock valued at $1,551,000 after purchasing an additional 285,910 shares in the last quarter. Baldwin Brothers Inc. MA boosted its holdings in Amgen by 0.4% in the 2nd quarter. Baldwin Brothers Inc. MA now owns 65,971 shares of the medical research company’s stock valued at $12,178,000 after purchasing an additional 293 shares in the last quarter. Benedict Financial Advisors Inc. boosted its holdings in Amgen by 2.4% in the 2nd quarter. Benedict Financial Advisors Inc. now owns 24,001 shares of the medical research company’s stock valued at $4,430,000 after purchasing an additional 573 shares in the last quarter. OLD Point Trust & Financial Services N A boosted its holdings in Amgen by 8.5% in the 2nd quarter. OLD Point Trust & Financial Services N A now owns 27,907 shares of the medical research company’s stock valued at $5,151,000 after purchasing an additional 2,195 shares in the last quarter. Finally, Moody Lynn & Lieberson LLC purchased a new stake in Amgen in the 2nd quarter valued at approximately $745,000. 77.91% of the stock is currently owned by hedge funds and other institutional investors.

AMGN stock opened at $192.77 on Friday. Amgen, Inc. has a 12-month low of $163.31 and a 12-month high of $210.19. The company has a debt-to-equity ratio of 2.05, a current ratio of 3.08 and a quick ratio of 2.84. The company has a market cap of $122.84 billion, a PE ratio of 13.89, a P/E/G ratio of 2.00 and a beta of 1.37.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, October 30th. The medical research company reported $3.69 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.45 by $0.24. Amgen had a net margin of 9.44% and a return on equity of 54.14%. The company had revenue of $5.90 billion during the quarter, compared to the consensus estimate of $5.78 billion. During the same period last year, the firm earned $3.27 EPS. The company’s revenue for the quarter was up 2.3% on a year-over-year basis. On average, analysts forecast that Amgen, Inc. will post 14.24 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 7th. Investors of record on Friday, November 16th will be given a dividend of $1.32 per share. The ex-dividend date of this dividend is Thursday, November 15th. This represents a $5.28 annualized dividend and a dividend yield of 2.74%. Amgen’s dividend payout ratio is currently 41.97%.

A number of brokerages have weighed in on AMGN. Cann reaffirmed a “buy” rating and issued a $224.00 price objective on shares of Amgen in a report on Monday, October 1st. Jefferies Financial Group reaffirmed a “buy” rating and issued a $220.00 price objective on shares of Amgen in a report on Monday, October 1st. Oppenheimer reaffirmed a “buy” rating and issued a $224.00 price objective on shares of Amgen in a report on Tuesday, October 2nd. Royal Bank of Canada set a $193.00 price objective on Amgen and gave the company a “neutral” rating in a report on Friday, September 28th. Finally, Zacks Investment Research raised Amgen from a “hold” rating to a “buy” rating and set a $234.00 price objective on the stock in a report on Monday, October 1st. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $204.55.

TRADEMARK VIOLATION NOTICE: “ClariVest Asset Management LLC Has $70.51 Million Holdings in Amgen, Inc. (AMGN)” was first published by WKRB News and is the property of of WKRB News. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. & international copyright law. The original version of this article can be viewed at https://www.wkrb13.com/2018/11/23/clarivest-asset-management-llc-has-70-51-million-holdings-in-amgen-inc-amgn.html.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Further Reading: How does inflation affect different investments?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply